Strides Shasun gets USFDA nod for pain relieving drug
New Delhi: Drug firm Strides Shasun has received the US health regulator's nod for Amantadine Hydrochloride tablets, used in the treatment of Parkinson's disease and Shingles to reduce pain.
"The product received approval in 15 months under the new GDUFA regime," Strides Shasun said in a regulatory filing.
"Strides Shasun... has received approval from the USFDA for Amantadine Hydrochloride tablets 100 mg," it said.
According to IMS data, the US market for this product is approximately $22 million (around Rs 141 crore) with two generic players. The product will be launched immediately.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd